Skip to main content
editorial
. 2022 Dec;10(23):1292. doi: 10.21037/atm-2022-65

Figure 1.

Figure 1

Outline of this issue. Relationship between therapy-related myeloid neoplasms and clonal hematopoiesis with indeterminate potential after PARP inhibitor treatment for platinum-sensitive ovarian cancer. PPM1D, protein phosphatase magnesium/manganese-dependent 1D; ATM, ataxia telangiectasia mutated; PARP, poly (ADP-ribose) polymerase; TP53, transformation-related protein 53.